Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Home
/
update
/
details

ICMR Collaborates with Industry and Academia to Initiate First-in-Human Phase 1 Clinical Trials

NextEdge Admin

14 Sep 2024

2 min 18 sec

In a major move to bolster India's clinical research landscape, the Indian Council of Medical Research (ICMR) has signed Memorandum of Agreements (MoAs) with multiple sponsors as part of its Network for phase 1 clinical trials. This marks India’s entry into first-in-human clinical trials for four innovative molecules.

The partnerships include research on a small molecule for multiple myeloma with Aurigene Oncology Limited, Zika vaccine development with Indian Immunologicals Limited, a seasonal influenza vaccine trial with Mynvax Private Limited, and a CAR-T cell therapy study for chronic lymphocytic leukemia with ImmunoACT.

This initiative positions India as a leader in the clinical development of pharmaceutical agents, according to the Union Health Ministry. Union Health Minister J.P. Nadda hailed the collaboration as a significant milestone towards making cutting-edge treatments affordable and accessible to all.

Dr. Rajiv Bahl, Secretary of the Department of Health Research and Director General of ICMR, emphasized the importance of strategic public-private partnerships in advancing clinical research. He noted that the phase 1 clinical trial network aims to develop indigenous molecules and innovative treatments, reflecting ICMR’s commitment to affordable healthcare.

The network includes four premier institutions across India—KEMH & GSMC in Mumbai, ACTREC in Navi Mumbai, SRM MCH&RC in Kattankulathur, and PGIMER in Chandigarh—backed by a Central Coordinating Unit at ICMR headquarters in New Delhi. These agreements strengthen ICMR's partnerships with industry and academia, furthering India’s leadership in clinical research.